

Thomas K Karikari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7861842/publications.pdf>

Version: 2024-02-01

382
papers

20,740
citations

17440

63
h-index

16183

124
g-index

422
all docs

422
docs citations

422
times ranked

22377
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	3.6	5
2	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.8	89
3	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	9.0	38
4	Plasma p-tau ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536.	0.8	18
5	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	7.6	20
6	Plasma p-tau231, p-tau181, ^{PET} Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	5.3	42
7	Circulating Metabolome and White Matter Hyperintensities in Women and Men. Circulation, 2022, 145, 1040-1052.	1.6	17
8	Amyloid processing in ^{COVID}-associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	3.9	35
9	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	6.1	65
10	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	6.2	49
11	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	6.1	34
12	A three- ϵ approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12270.	3.7	3
13	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
14	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	7.7	89
15	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	1.1	3
16	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	1.9	12
17	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
18	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26

#	ARTICLE	IF	CITATIONS
19	Associations of β -Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. <i>Neurology</i> , 2022, 99, .	1.1	12
20	Familial British dementia: a clinical and multi-modal imaging case study. <i>Journal of Neurology</i> , 2022, 269, 3926-3930.	3.6	2
21	Blood biomarkers for Alzheimer's disease and related disorders. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 51-55.	2.1	28
22	Effect of Race on Prediction of Brain Amyloidosis by Plasma $A\beta_{42}/A\beta_{40}$, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.1	63
23	Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	2.6	8
24	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	11.6	73
25	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	1.5	16
26	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557.	7.6	15
27	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65.	6.2	25
28	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	10.1	99
29	Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 693-700.	1.9	26
30	Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A91.2-A91.	1.9	0
31	Investigating the use of plasma pTau181 in retired contact sports athletes. <i>Journal of Neurology</i> , 2022, 269, 5582-5595.	3.6	4
32	Comorbidities confound Alzheimer's blood tests. <i>Nature Medicine</i> , 2022, 28, 1349-1351.	30.7	12
33	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	7.9	76
34	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021, 36, 632-641.	3.9	3
35	Genetic testing in dementia – utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021, 17, 23-36.	10.1	26
36	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.8	81

#	ARTICLE	IF	CITATIONS
37	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	7.6	124
38	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	1.6	80
39	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	7.9	186
40	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	2.4	52
41	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. <i>European Radiology</i> , 2021, 31, 5312-5323.	4.5	19
42	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	6.2	35
43	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12131.	2.4	19
44	Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1617-1629.	3.6	8
45	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	7.7	285
46	Plasma p-tau181 to A β 242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662.	0.8	37
47	A population-based study of head injury, cognitive function and pathological markers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 842-856.	3.7	5
48	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156.	6.4	83
49	Synedrella nodiflora Extract Depresses Excitatory Synaptic Transmission and Chemically-Induced In Vitro Seizures in the Rat Hippocampus. <i>Frontiers in Pharmacology</i> , 2021, 12, 610025.	3.5	2
50	New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology</i> , The, 2021, 20, 222-234.	10.2	214
51	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 65.	6.2	49
52	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	6.2	34
53	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. <i>Molecular Psychiatry</i> , 2021, 26, 5955-5966.	7.9	30
54	When dementia is misdiagnosed. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 799-801.	2.7	3

#	ARTICLE	IF	CITATIONS
55	Investigating the relationship between BMI across adulthood and late life brain pathologies. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 91.	6.2	7
56	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	3.3	15
57	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
58	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. <i>Brain</i> , 2021, 144, 2946-2953.	7.6	46
59	KL ϵ -VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE ϵ -4 carriers. <i>Neurobiology of Aging</i> , 2021, 101, 123-129.	3.1	10
60	Subjective cognitive complaints at age 70: associations with amyloid and mental health. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1215-1221.	1.9	16
61	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
62	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
63	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	12.8	219
64	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	3.3	33
65	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.1	50
66	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	12.8	33
67	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	30.7	235
68	Aducanumab: a new phase in therapeutic development for Alzheimer's disease?. <i>EMBO Molecular Medicine</i> , 2021, 13, e14781.	6.9	47
69	Reply: Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2021, 144, e73.	7.6	2
70	Grip strength from midlife as an indicator of later-life brain health and cognition: evidence from a British birth cohort. <i>BMC Geriatrics</i> , 2021, 21, 475.	2.7	18
71	Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations. <i>Movement Disorders</i> , 2021, 36, 2481-2493.	3.9	15
72	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	9.0	114

#	ARTICLE	IF	CITATIONS
73	Sex-related differences in whole brain volumes at age 70 in association with hyperglycemia during adult life. <i>Neurobiology of Aging</i> , 2021, 112, 161-169.	3.1	1
74	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	1.9	51
75	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	3.1	5
76	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab003.	3.3	8
77	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.8	174
78	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099.	3.3	43
79	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	7.6	54
80	The global Alzheimer's Association round robin study on plasma amyloid β^2 methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242.	2.4	17
81	Dissociable effects of APOE ϵ^4 and β^2 -amyloid pathology on visual working memory. <i>Nature Aging</i> , 2021, 1, 1002-1009.	11.6	16
82	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	6.9	30
83	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
84	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021, 4, 1265.	4.4	4
85	Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. <i>Brain Communications</i> , 2021, 3, fcab272.	3.3	18
86	Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 188.	6.2	8
87	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer's disease in the UK. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
88	Menopause and later-life cognition: Findings from the longest-running population-based birth cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
89	Implementation of remote neuropsychological assessments in the Insight 46 study: Lessons learned from the transition to videoconferencing and telephone assessments. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
90	Atrophy and partial volume related bias in cortical region of interest NODDI metrics. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
91	Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
92	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
93	Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β 2 pathology and preclinical application. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
94	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
95	Disentangling axonal loss and demyelination using multi-modal imaging: Application to young onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
96	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
97	Plasma p-tau181 and p-tau231 offer complementary information to identify Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
98	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
99	The heterogeneous brain: Mapping individualised patterns of atrophy in Alzheimer's disease using spatial normative models. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
100	Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
101	Plasma p-tau ₁₈₁ and NfL are central nodes in a network of diagnostic, biomarker, and demographic data. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
102	Impact of polygenic risk score on normative models of hippocampal volumes. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
103	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
104	CSF and blood biomarkers: How strongly do they reflect Alzheimer's pathophysiology and are they dynamic?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
105	Fixel-based analysis of the effect of amyloid beta on white matter tracts in neurologically normal 70 year olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
106	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
107	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020, 25, 2919-2931.	7.9	99
108	Construction and reconstruction of brain circuits: normal and pathological axon guidance. <i>Journal of Neurochemistry</i> , 2020, 153, 10-32.	3.9	18

#	ARTICLE	IF	CITATIONS
109	Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life. JAMA Neurology, 2020, 77, 175.	9.0	55
110	Diet quality in late midlife is associated with faster walking speed in later life in women, but not men: findings from a prospective British birth cohort. British Journal of Nutrition, 2020, 123, 913-921.	2.3	3
111	Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches. Frontiers in Molecular Neuroscience, 2020, 13, 155.	2.9	20
112	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. Nature Communications, 2020, 11, 3960.	12.8	20
113	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	7.7	209
114	Increased variability in reaction time is associated with amyloid beta pathology at age 70. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12076.	2.4	8
115	Functional cognitive disorder: dementia's blind spot. Brain, 2020, 143, 2895-2903.	7.6	84
116	Diffuse axonal injury predicts neurodegeneration after moderate-to-severe traumatic brain injury. Brain, 2020, 143, 3685-3698.	7.6	69
117	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 112.	6.2	18
118	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	2.6	55
119	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. ACS Chemical Neuroscience, 2020, 11, 3117-3129.	3.5	6
120	Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. Acta Neuropathologica, 2020, 140, 863-879.	7.7	18
121	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
122	Plasma phospho-tau181 in over 400 cognitively healthy 69- to 71-year-olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.8	0
123	Vascular risk factors and amyloid pathology: Additive or interactive associations?. Alzheimer's and Dementia, 2020, 16, e037922.	0.8	0
124	The differential genetic architecture between posterior cortical atrophy and amnesic Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e038851.	0.8	1
125	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. Alzheimer's and Dementia, 2020, 16, e039557.	0.8	2
126	Uncovering superficial white matter changes in young-onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039746.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Performance on the graded naming test in a population-based sample of 72-year-olds: Associations with life-course predictors and β -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e040897.	0.8	0
128	Accelerated forgetting is sensitive to β -amyloid pathology and cerebral atrophy in cognitively normal 72-year-olds. <i>Alzheimer's and Dementia</i> , 2020, 16, e040987.	0.8	0
129	APOE ϵ 4 carriers have superior recall on the "What was where?" visual short-term memory binding test at age 70, despite a detrimental effect of β -amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e041090.	0.8	4
130	Lifetime cigarette smoking and later-life brain health: The population-based 1946 British Birth Cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e041111.	0.8	1
131	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer's and Dementia</i> , 2020, 16, e041808.	0.8	1
132	Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e041849.	0.8	1
133	Plasma phospho-tau in familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042921.	0.8	0
134	Cerebral amyloid and white matter hyperintensity volume are independently associated with rates of cerebral atrophy in Insight 46, a sub-study of the 1946 British birth cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e044924.	0.8	0
135	CSF phosphorylated tau ϵ 217 is increased in Alzheimer's and Creutzfeldt-Jakob diseases and correlates with amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e045296.	0.8	4
136	Augmenting cognitive assessment with instruction-less Eye-tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e045318.	0.8	0
137	An extensive plasmid library for preparing tau variants and studying their functional biochemistry. <i>Alzheimer's and Dementia</i> , 2020, 16, e045387.	0.8	0
138	Augmenting cognitive assessment with instruction-less eye-tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e045483.	0.8	0
139	Mid-life blood pressure and microstructural white matter: Findings from the 1946 British birth cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045707.	0.8	0
140	Multimodal modelling of the heterogeneity of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045822.	0.8	1
141	Serum neurofilament light and whole brain volume associate with machine-learning derived brain-predicted age in the British 1946 birth cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045965.	0.8	1
142	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045991.	0.8	0
143	Plasma-based biomarkers for β and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046490.	0.8	0
144	Plasma p-tau ϵ 181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.8	2

#	ARTICLE	IF	CITATIONS
145	How to diagnose difficult white matter disorders. Practical Neurology, 2020, 20, 280-286.	1.1	3
146	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	1.9	93
147	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 2020, 143, 3104-3120.	7.6	880
148	Olfactory testing does not predict β -amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort. Journal of Neurology, 2020, 267, 3329-3336.	3.6	4
149	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	6.2	32
150	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Dementia and Geriatric Cognitive Disorders, 2020, 49, 56-76.	1.5	27
151	Pure tone audiometry and cerebral pathology in healthy older adults. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 172-176.	1.9	16
152	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	5.7	45
153	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	1.6	39
154	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	2.6	38
155	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
156	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
157	The C291R Tau Variant Forms Different Types of Protofibrils. Frontiers in Molecular Neuroscience, 2020, 13, 39.	2.9	10
158	A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond APOE. Brain Communications, 2020, 2, fcz047.	3.3	45
159	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. Alzheimer's and Dementia, 2020, 16, e043060.	0.8	0
160	Study Protocol "Insight 46 Cardiovascular: A Sub-study of the MRC National Survey of Health and Development. Artery Research, 2020, 26, 170-179.	0.6	2
161	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurology, The, 2019, 18, 942-952.	10.2	178
162	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9

#	ARTICLE	IF	CITATIONS
163	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 62.	6.2	40
164	Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 296.	3.7	36
165	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. <i>PLoS ONE</i> , 2019, 14, e0224030.	2.5	26
166	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. <i>NeuroImage: Clinical</i> , 2019, 24, 102051.	2.7	7
167	Cognition at age 70. <i>Neurology</i> , 2019, 93, e2144-e2156.	1.1	37
168	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	3.7	34
169	Looking beyond the eyes: visual impairment in posterior cortical atrophy. <i>Lancet, The</i> , 2019, 394, 1055.	13.7	1
170	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.0	455
171	SILK studies – capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	10.1	37
172	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. <i>Brain</i> , 2019, 142, 2082-2095.	7.6	64
173	International Science Education. <i>Journal of Microbiology and Biology Education</i> , 2019, 20, 10.	1.0	3
174	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. <i>Scientific Reports</i> , 2019, 9, 4191.	3.3	17
175	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 740-746.	1.9	23
176	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid- β 2 copathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 277-280.	2.4	24
177	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 19.	6.2	65
178	Biomarkers for Alzheimer's disease beyond amyloid and tau. <i>Nature Medicine</i> , 2019, 25, 201-203.	30.7	34
179	The functional neuroanatomy of musical memory in Alzheimer's disease. <i>Cortex</i> , 2019, 115, 357-370.	2.4	20
180	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates β 2, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962

#	ARTICLE	IF	CITATIONS
181	ICâ€Pâ€007: CENTILOID SCALE TRANSFORMATION OF FLORBETAPIR DATA ACQUIRED ON A PET/MR SCANNER. Alzheimer's and Dementia, 2019, 15, P17.	0.8	0
182	CSF synaptic protein concentrations are raised in those with atypical Alzheimerâ€™s disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105.	6.2	31
183	P4â€490: ALZHEIMER'S DISEASE POLYGENIC BURDEN BEYOND APOE ACTS STRONGER ON TAU THAN ON AMYLOID. Alzheimer's and Dementia, 2019, 15, P1500.	0.8	0
184	O4â€13â€01: EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69â€71 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P1269.	0.8	0
185	Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. BMJ Open, 2019, 9, e029502.	1.9	16
186	ICâ€Pâ€006: LONGITUDINAL RATES OF AMYLOID ACCUMULATION IN A 70â€YEAR OLD BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P16.	0.8	0
187	Sleep symptoms in syndromes of frontotemporal dementia and Alzheimerâ€™s disease: A proof-of-principle behavioural study. ENeurologicalSci, 2019, 17, 100212.	1.3	17
188	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASLâ€MRI: proof of concept. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2419-2432.	4.3	11
189	Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease. NeuroImage: Clinical, 2019, 21, 101632.	2.7	37
190	Unsuccessful trials of therapies for Alzheimer's disease. Lancet, The, 2019, 393, 29.	13.7	31
191	Learnings about the complexity of extracellular tau aid development of a bloodâ€based screen for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 487-496.	0.8	94
192	Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 543-555.	1.9	87
193	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
194	Preparation of stable tau oligomers for cellular and biochemical studies. Analytical Biochemistry, 2019, 566, 67-74.	2.4	35
195	CSF Beta-amyloid 1â€42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. Annals of Surgery, 2019, 269, 1200-1205.	4.2	56
196	Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity. ENeuro, 2019, 6, ENEURO.0166-19.2019.	1.9	42
197	Differences in topological progression profile among neurodegenerative diseases from imaging data. ELife, 2019, 8, .	6.0	11
198	Title is missing!. , 2019, 14, e0224030.		0

#	ARTICLE	IF	CITATIONS
199	Title is missing!. , 2019, 14, e0224030.		0
200	Title is missing!. , 2019, 14, e0224030.		0
201	Title is missing!. , 2019, 14, e0224030.		0
202	Susceptibility of brain atrophy to <i>TRIB3</i> in Alzheimer's disease, evidence from functional prioritization in imaging genetics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3162-3167.	7.1	41
203	Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging. Human Brain Mapping, 2018, 39, 3005-3017.	3.6	87
204	Primary progressive aphasia: a clinical approach. Journal of Neurology, 2018, 265, 1474-1490.	3.6	185
205	Plasma tau is increased in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 804-807.	1.9	41
206	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2018, 17, 123-132.	10.2	84
207	Motor signatures of emotional reactivity in frontotemporal dementia. Scientific Reports, 2018, 8, 1030.	3.3	31
208	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	3.7	30
209	Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	2.4	21
210	Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain, 2018, 141, 1529-1544.	7.6	111
211	Apolipoprotein E genotypes and longevity across dementia disorders. Alzheimer's and Dementia, 2018, 14, 895-901.	0.8	8
212	Cerebrospinal fluid in the dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.8	9
213	ICA-P&C151: AN EVENT-BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE. Alzheimer's and Dementia, 2018, 14, P129.	0.8	0
214	P3&C196: DISTINCT CONFORMATIONS, AGGREGATION AND NEURONAL PROPAGATION OF DIFFERENT TAU STRAINS. Alzheimer's and Dementia, 2018, 14, P1142.	0.8	0
215	P1&C267: CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION. Alzheimer's and Dementia, 2018, 14, P384.	0.8	0
216	P3&C420: AN EVENT BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE. Alzheimer's and Dementia, 2018, 14, P1268.	0.8	0

#	ARTICLE	IF	CITATIONS
217	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.8	0
218	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
219	P2â€390: DIFFERENTIAL HIPPOCAMPAL SUBFIELD LOSS IN DIFFERENT PHENOTYPES OF YOUNG ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P850.	0.8	1
220	O3â€14â€04: THE PROTEINâ€TOâ€PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULEâ€ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. Alzheimer's and Dementia, 2018, 14, P1060.	0.8	0
221	P3â€437: LONGITUDINAL CORTICAL THICKNESS IN SPORADIC YOUNG ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
222	ICâ€Pâ€076: GENOMEWIDE ASSOCIATION STUDY OF DATAâ€DRIVEN ALZHEIMER'S DISEASE SUBTYPES. Alzheimer's and Dementia, 2018, 14, P67.	0.8	0
223	O3â€10â€04: GENOMEWIDE ASSOCIATION STUDY OF DATAâ€DRIVEN ALZHEIMER'S DISEASE SUBTYPES. Alzheimer's and Dementia, 2018, 14, P1042.	0.8	1
224	P1â€474: SURFACEâ€BASED ANALYSIS OF CORTICAL GREY MATTER MICROSTRUCTURE IN YOUNGâ€ONSET ALZHEIMER'S DISEASE USING NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING (NODDI). Alzheimer's and Dementia, 2018, 14, P505.	0.8	0
225	Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Research Notes, 2018, 11, 885.	1.4	37
226	Medicinal Plants Used in the Treatment of Mental and Neurological Disorders in Ghana. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-14.	1.2	28
227	O2â€05â€01: INFLUENCES OF BLOOD PRESSURE AND BLOOD PRESSURE TRAJECTORIES ON CEREBRAL PATHOLOGY AT AGE 70: RESULTS FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2018, 14, P626.	0.8	1
228	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0
229	P1â€301: CERTAIN PLASMA Nâ€TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.8	0
230	P1â€031: HEAD INJURY WITH LOSS OF CONSCIOUSNESS AND SUBSEQUENT COGNITIVE DECLINE: FOLLOWâ€UP IN THE 1946 BRITISH BIRTH COHORT STUDY. Alzheimer's and Dementia, 2018, 14, P278.	0.8	1
231	Prevalence of amyloidâ€ ^{Î²} pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
232	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
233	Navigating Genetic Influences on the Topography of Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 84, 476-477.	1.3	0
234	Clinicopathological case: progressive somnolence and dementia in an accountant: when the shine rubs off the gold standard. Practical Neurology, 2018, 18, 505-512.	1.1	0

#	ARTICLE	IF	CITATIONS
235	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	12.6	1,085
236	Commentary: Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018, 9, 201.	2.4	31
237	Stability of bloodâ€based biomarkers of Alzheimer's disease over multiple freezeâ€thaw cycles. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 448-451.	2.4	49
238	Cerebrospinal fluid in the differential diagnosis of Alzheimerâ€™s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	6.2	79
239	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	163
240	An extract of <i>Synedrella nodiflora</i> (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms. <i>Metabolic Brain Disease</i> , 2018, 33, 1359-1368.	2.9	8
241	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 79.	6.2	43
242	Genetic study of multimodal imaging Alzheimerâ€™s disease progression score implicates novel loci. <i>Brain</i> , 2018, 141, 2167-2180.	7.6	56
243	Aide-mÃ©moires in semantic dementia. <i>Practical Neurology</i> , 2018, 18, 334-335.	1.1	0
244	Kenya and Ghana set up national research funding schemes. <i>Nature</i> , 2018, 557, 166-166.	27.8	3
245	Redefining the phenotype of ALSP and <i>AARS2</i> mutationâ€related leukodystrophy. <i>Neurology: Genetics</i> , 2017, 3, e135.	1.9	64
246	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.8	423
247	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.	1.9	78
248	Imaging the ageing brain: identifying early disease or opening Pandora's box?. <i>Lancet Neurology</i> , The, 2017, 16, 411-413.	10.2	2
249	ApoE influences regional white-matter axonal density loss in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 57, 8-17.	3.1	82
250	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimerâ€™s disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 767-775.	2.8	4
251	Clinical and genetic characterization of leukoencephalopathies in adults. <i>Brain</i> , 2017, 140, 1204-1211.	7.6	73
252	Cognitive decline before diagnosis of Parkinson's disease â€ Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 262.	10.2	2

#	ARTICLE	IF	CITATIONS
253	A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset. <i>Neuroinformatics</i> , 2017, 15, 215-226.	2.8	14
254	Serum neurofilament light in familial Alzheimer disease. <i>Neurology</i> , 2017, 89, 2167-2175.	1.1	204
255	An ethanolic extract of <i>Desmodium adscendens</i> exhibits antipsychotic-like activity in mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2017, 28, 507-518.	1.3	3
256	[P4â€“004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P12.	0.8	0
257	Inhibiting the Ca ²⁺ Influx Induced by Human CSF. <i>Cell Reports</i> , 2017, 21, 3310-3316.	6.4	20
258	[P4â€“261]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1382.	0.8	0
259	[P1â€“443]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P453.	0.8	1
260	[P4â€“079]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P65.	0.8	0
261	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	10.2	464
262	Study protocol: Insight 46 â€“ a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017, 17, 75.	1.8	64
263	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 13-22.	3.8	29
264	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 66-75.	10.2	304
265	Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. <i>Protein Expression and Purification</i> , 2017, 130, 44-54.	1.3	35
266	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	2.6	6
267	[P2â€“414]: CHARACTERISING THE PROGRESSION OF ALZHEIMER'S DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P791.	0.8	0
268	[P2â€“545]: VASCULAR AND EARLY LIFE INFLUENCES ON CEREBROVASCULAR DISEASE IN INSIGHT 46: A SUBâ€“STUDY OF THE MRC NATIONAL SURVEY OF HEALTH AND DEVELOPMENT (NSHD) BRITISH BIRTH COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P851.	0.8	0
269	[P3â€“348]: EXPLORING THE POPULATION PREVALENCE OF β -AMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946. <i>Alzheimer's and Dementia</i> , 2017, 13, P1088.	0.8	0
270	[P3â€“373]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P1100.	0.8	0

#	ARTICLE	IF	CITATIONS
271	[P4â€“230]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€“ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1359.	0.8	0
272	[ICâ€“Pâ€“047]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN INâ€“VIVO STUDY OF THE ADNI COHORT. Alzheimer's and Dementia, 2017, 13, P40.	0.8	1
273	[ICâ€“Pâ€“154]: CHARACTERISING THE PROGRESSION OF ALZHEIMER'S DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). Alzheimer's and Dementia, 2017, 13, P116.	0.8	2
274	[ICâ€“Pâ€“168]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€“ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P127.	0.8	0
275	[P1â€“335]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT. Alzheimer's and Dementia, 2017, 13, P384.	0.8	0
276	[P1â€“348]: CSF AÎ²42 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION. Alzheimer's and Dementia, 2017, 13, P390.	0.8	0
277	[P1â€“465]: PROGRESSIVE CALLOSAL ATROPHY WITH STABLE MEMORY IMPAIRMENT IN FAMILIAL BRITISH DEMENTIA. Alzheimer's and Dementia, 2017, 13, P465.	0.8	0
278	[P2â€“241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.8	0
279	[O1â€“10â€“03]: BIOMARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P215.	0.8	1
280	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
281	[O5â€“05â€“04]: BRAIN VOLUME, CEREBRAL Î²â€“AMYLOID DEPOSITION, AND AGEING: A STUDY OF OVER 200 INDIVIDUALS BORN IN THE SAME WEEK IN 1946. Alzheimer's and Dementia, 2017, 13, P1464.	0.8	0
282	Eyetracking Metrics in Young Onset Alzheimerâ€™s Disease: A Window into Cognitive Visual Functions. Frontiers in Neurology, 2017, 8, 377.	2.4	50
283	Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimerâ€™s Disease. Frontiers in Neurology, 2017, 8, 580.	2.4	42
284	A Model Approach to Public Engagement Training for Students in Developing Countries. Journal of Microbiology and Biology Education, 2017, 18, .	1.0	2
285	Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. BMC Complementary and Alternative Medicine, 2017, 17, 389.	3.7	17
286	Current concepts and controversies in the pathogenesis of Parkinsonâ€™s disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	1.6	35
287	[P2â€“409]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN INâ€“VIVO STUDY OF THE ADNI COHORT. Alzheimer's and Dementia, 2017, 13, P788.	0.8	1
288	Build the Future of Science Communication in Developing Countries through Systematic Training of Young Scientists. Journal of Microbiology and Biology Education, 2016, 17, 327-328.	1.0	2

#	ARTICLE	IF	CITATIONS
289	Social Factors Influencing Child Health in Ghana. PLoS ONE, 2016, 11, e0145401.	2.5	37
290	Music Perception in Dementia. Journal of Alzheimer's Disease, 2016, 55, 933-949.	2.6	34
291	Assessment of the quality of groundwater for drinking purposes in the Upper West and Northern regions of Ghana. SpringerPlus, 2016, 5, 2001.	1.2	34
292	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	2.6	21
293	The palmomental reflex: stop scratching around!. Practical Neurology, 2016, 16, 500-501.	1.1	5
294	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
295	Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. Clinical Neurology and Neurosurgery, 2016, 144, 64-66.	1.4	1
296	A physiological signature of sound meaning in dementia. Cortex, 2016, 77, 13-23.	2.4	18
297	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiology of Aging, 2016, 39, 99-107.	3.1	34
298	Potential role of metabolomics in the improvement of research on traditional African medicine. Phytochemistry Letters, 2016, 17, 270-277.	1.2	10
299	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87, 1329-1336.	1.1	354
300	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
301	Multimodal Image Analysis in Alzheimer's Disease via Statistical Modelling of Non-local Intensity Correlations. Scientific Reports, 2016, 6, 22161.	3.3	18
302	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1032-1034.	1.9	9
303	Academic dishonesty in higher education: students' perceptions and involvement in an African institution. BMC Research Notes, 2016, 9, 234.	1.4	18
304	Functional neuroanatomy of spatial sound processing in Alzheimer's disease. Neurobiology of Aging, 2016, 39, 154-164.	3.1	25
305	Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy. Neurobiology of Aging, 2016, 44, 108-113.	3.1	11
306	Neuroscience-related research in Ghana: a systematic evaluation of direction and capacity. Metabolic Brain Disease, 2016, 31, 11-24.	2.9	9

#	ARTICLE	IF	CITATIONS
307	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.1	170
308	Disregard of neurological impairments associated with neglected tropical diseases in Africa. <i>ENeurologicalSci</i> , 2016, 3, 11-14.	1.3	12
309	The habenula: an under-recognised area of importance in frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 910-912.	1.9	14
310	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.	7.6	174
311	Characterization of tau positron emission tomography tracer [¹⁸ F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. <i>Alzheimer's and Dementia</i> , 2016, 12, 1116-1124.	0.8	161
312	Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?. <i>Brain</i> , 2016, 139, 647-650.	7.6	4
313	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1000-1004.	1.9	62
314	Building sustainable neuroscience capacity in Africa: the role of non-profit organisations. <i>Metabolic Brain Disease</i> , 2016, 31, 3-9.	2.9	30
315	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	2
316	Evaluation of Changes in Ghanaian Students' Attitudes Towards Science Following Neuroscience Outreach Activities: A Means to Identify Effective Ways to Inspire Interest in Science Careers. <i>Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience</i> , 2016, 14, A117-23.	0.0	5
317	Developing Science Communication in Africa: Undergraduate and Graduate Students should be Trained and Actively Involved in Outreach Activity Development and Implementation. <i>Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience</i> , 2016, 14, E5-8.	0.0	3
318	P4-189: Effect of brain-specific kinase-dependent tau phosphorylation on tauopathy-associated sundowning sleep behaviour. , 2015, 11, P852-P852.		0
319	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical ^{AD} subjects. <i>Human Brain Mapping</i> , 2015, 36, 5123-5136.	3.6	19
320	Do cerebrospinal fluid transfer methods affect measured amyloid β 42, total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	2.4	5
321	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	2.4	16
322	Letter to the Editor. <i>Journal of Microbiology and Biology Education</i> , 2015, 16, 3-4.	1.0	9
323	Dementias show differential physiological responses to salient sounds. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 73.	2.0	21
324	Altered Sense of Humor in Dementia. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 111-119.	2.6	39

#	ARTICLE	IF	CITATIONS
325	Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	29
326	Auditory spatial processing in Alzheimer's disease. <i>Brain</i> , 2015, 138, 189-202.	7.6	49
327	Developing expertise in bioinformatics for biomedical research in Africa. <i>Applied & Translational Genomics</i> , 2015, 6, 31-34.	2.1	28
328	Neurogenomics: An opportunity to integrate neuroscience, genomics and bioinformatics research in Africa. <i>Applied & Translational Genomics</i> , 2015, 5, 3-10.	2.1	21
329	Widening participation would be key in enhancing bioinformatics and genomics research in Africa. <i>Applied & Translational Genomics</i> , 2015, 6, 35-41.	2.1	4
330	Neurogenomics: Challenges and opportunities for Ghana. <i>Applied & Translational Genomics</i> , 2015, 5, 11-14.	2.1	4
331	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015, 10, 64.	10.8	121
332	Clinical relevance of serum antibodies to extracellular α -methyl-d-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 708-713.	1.9	97
333	Humour processing in frontotemporal lobar degeneration: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015, 69, 47-59.	2.4	42
334	White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2015, 8, 640-651.	2.7	65
335	Identification of environmental sounds and melodies in syndromes of anterior temporal lobe degeneration. <i>Journal of the Neurological Sciences</i> , 2015, 352, 94-98.	0.6	23
336	Functional neuroanatomy of auditory scene analysis in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 699-708.	2.7	43
337	Cerebrospinal fluid tau and amyloid- β_{1-42} in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	7.6	152
338	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. <i>Brain</i> , 2015, 138, 1976-1991.	7.6	74
339	New criteria for Alzheimer's disease: which, when and why?. <i>Brain</i> , 2015, 138, 1134-1137.	7.6	12
340	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1225-1233.	1.9	114
341	Dissecting IWC-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015, 262, 2722-2730.	3.6	39
342	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 3140-3151.	3.1	53

#	ARTICLE	IF	CITATIONS
343	Physiological phenotyping of dementias using emotional sounds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 170-178.	2.4	21
344	A simulation system for biomarker evolution in neurodegenerative disease. <i>Medical Image Analysis</i> , 2015, 26, 47-56.	11.6	13
345	Picturing the torment of cluster headache. <i>Neurology</i> , 2015, 85, 1430-1431.	1.1	0
346	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. <i>Brain</i> , 2015, 138, 3360-3372.	7.6	90
347	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015, 123, 149-164.	4.2	63
348	Auditory hedonic phenotypes in dementia: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015, 67, 95-105.	2.4	48
349	Bridging the gap: Introducing neuroscience to Ghana. <i>Biochemist</i> , 2015, 37, 46-47.	0.5	6
350	Bioinformatics in Africa: The Rise of Ghana?. <i>PLoS Computational Biology</i> , 2015, 11, e1004308.	3.2	45
351	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1016-1023.	1.9	31
352	Prominent effects and neural correlates of visual crowding in a neurodegenerative disease population. <i>Brain</i> , 2014, 137, 3284-3299.	7.6	36
353	Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. <i>JAMA Neurology</i> , 2014, 71, 421.	9.0	51
354	A data-driven model of biomarker changes in sporadic Alzheimer's disease. <i>Brain</i> , 2014, 137, 2564-2577.	7.6	243
355	Amyloid-beta 42 adsorption following serial tube transfer. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 5.	6.2	39
356	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953.	1.1	213
357	<i>R47H TREM2</i> variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 602.	0.8	94
358	P1-020: AUDITORY SPATIAL PROCESSING IN ALZHEIMER'S DISEASE AND POSTERIOR CORTICAL ATROPHY. , 2014, 10, P311-P311.		0
359	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS. , 2014, 10, P32-P33.		0
360	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI. , 2014, 10, P414-P415.		1

#	ARTICLE	IF	CITATIONS
361	O2â€05â€01: A DATAâ€DRIVEN MODEL OF BIOMARKER CHANGES IN SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2014, 10, P172.	0.8	3
362	P1-346: IDENTIFICATION OF ENVIRONMENTAL SOUNDS AND MELODIES IN SYNDROMES OF ANTERIOR TEMPORAL LOBE DEGENERATION. , 2014, 10, P440-P440.		0
363	O2-14-06: ABNORMALITIES OF FIXATION, SACCADÉ, AND PURSUIT IN POSTERIOR CORTICAL ATROPHY COMPARED TO TYPICAL AD. , 2014, 10, P199-P199.		1
364	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.		0
365	Inflammation in Alzheimerâ€™s disease: insights from immunotherapy. Brain, 2013, 136, 2654-2656.	7.6	38
366	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36
367	Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1486.e9-1486.e15.	3.1	25
368	Alzheimer's disease: mimics and chameleons. Practical Neurology, 2012, 12, 358-366.	1.1	19
369	Posterior cortical atrophy. Lancet Neurology, The, 2012, 11, 170-178.	10.2	487
370	Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials. Neurolmage, 2011, 57, 15-18.	4.2	69
371	Combining biomarkers: the future for Alzheimerâ€™s disease prevention studies?. Neurodegenerative Disease Management, 2011, 1, 175-178.	2.2	0
372	Suspected early dementia. BMJ: British Medical Journal, 2011, 343, d5568-d5568.	2.3	5
373	Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathologica, 2010, 120, 327-341.	7.7	64
374	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid AÎ²1â€42. Annals of Neurology, 2010, 68, 825-834.	5.3	150
375	Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain, 2010, 133, 3315-3322.	7.6	51
376	New developments in mild cognitive impairment and Alzheimer's disease. Current Opinion in Neurology, 2006, 19, 552-558.	3.6	25
377	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. Movement Disorders, 2003, 18, 955-958.	3.9	19
378	Assessing the onset of structural change in familial Alzheimer's disease. Annals of Neurology, 2003, 53, 181-188.	5.3	152

#	ARTICLE	IF	CITATIONS
379	A THREE-RANGE APPROACH ENHANCES PROGNOSTIC UTILITY OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE. , 0, , .		0
380	Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels in Down Syndrome and Sporadic Alzheimer'S Disease: A Cross-Sectional Study. SSRN Electronic Journal, 0, , .	0.4	0
381	Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery. British Journal of Surgery, 0, , .	0.3	2
382	Editorial: Blood Biomarkers of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	0